Summary: In this issue of Cancer Discovery, Miyamoto and colleagues adapted their microfluidic CTC-iChip isolation platform with a digital RNA-PCR readout for eight prostate-specific transcripts and two assays for the androgen receptor mRNA splice variant ARV7 and the TMPRSS2–ERG translocation transcript. In patients with metastatic castrate-resistant prostate cancer at initiating abiraterone therapy in a first-line setting, the resulting RNA-based digital circulating tumor cell signatures identified patients with a shorter overall survival, and in patients with clinically localized disease, the signatures identified those with seminal vesicle invasion and pelvic lymph node involvement. Cancer Discov; 8(3); 269–71. ©2018 AACR.

See related article by Miyamoto et al., p. 288.

简介：在本期《癌症发现》杂志中，Miyamoto及其同事将其微流控CTC-iChip分离平台改编为数字RNA-PCR读数，可读取八种前列腺特异性转录本，并对两种雄激素受体mRNA剪接变体ARV7和TMPRSS2-ERG易位进行了测定成绩单。在一线治疗中开始阿比特龙治疗的转移性去势抵抗性前列腺癌患者中，所得的基于RNA的数字循环肿瘤细胞特征识别出总体生存期较短的患者，而在临床局部疾病患者中，特征识别出了那些患者。伴有精囊侵犯和盆腔淋巴结受累。巨蟹座Discov; 8（3）；269–71。©2018 AACR。

参见Miyamoto等人的相关文章，第2页。288。